161 related articles for article (PubMed ID: 8917401)
1. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
[TBL] [Abstract][Full Text] [Related]
3. Prediction of the optimum clinical dosing schedule for menogaril from results with tumor-bearing mice.
Yoshida M; Kobunai T; Nakano K; Saito H; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(5A):2869-73. PubMed ID: 8917400
[TBL] [Abstract][Full Text] [Related]
4. In vitro evaluation of the new anticancer agents KT6149, MX-2, SM5887, menogaril, and liblomycin using cisplatin- or adriamycin-resistant human cancer cell lines.
Ohe Y; Nakagawa K; Fujiwara Y; Sasaki Y; Minato K; Bungo M; Niimi S; Horichi N; Fukuda M; Saijo N
Cancer Res; 1989 Aug; 49(15):4098-102. PubMed ID: 2472873
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
6. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
7. Superior antitumor activity of SAR3419 to rituximab in xenograft models for non-Hodgkin's lymphoma.
Al-Katib AM; Aboukameel A; Mohammad R; Bissery MC; Zuany-Amorim C
Clin Cancer Res; 2009 Jun; 15(12):4038-45. PubMed ID: 19509168
[TBL] [Abstract][Full Text] [Related]
8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
9. [In vivo assessment on the therapeutic effects of etoposide, vincristine and mitomycin C against human neuroblastoma].
Kaneko M; Kaneko S; Ohkawa H
Gan To Kagaku Ryoho; 1991 Jun; 18(7):1155-61. PubMed ID: 1905121
[TBL] [Abstract][Full Text] [Related]
10. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
[TBL] [Abstract][Full Text] [Related]
11. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors.
Kobayashi E; Okamoto A; Asada M; Okabe M; Nagamura S; Asai A; Saito H; Gomi K; Hirata T
Cancer Res; 1994 May; 54(9):2404-10. PubMed ID: 8162588
[TBL] [Abstract][Full Text] [Related]
13. The effect of adriamycin against a liver metastatic model by encapsulation in liposomes.
Yachi K; Suzuki N; Tanaka N; Okada K; Mitsui I; Kawato Y; Komagata Y; Komiyama K; Kikuchi H
Biopharm Drug Dispos; 1996 Nov; 17(8):699-715. PubMed ID: 8950048
[TBL] [Abstract][Full Text] [Related]
14. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
15. Cross-resistance of menogaril and mitoxantrone in a subline of P388 leukemia resistant to doxorubicin.
Chandrasekaran B; Dimling J; Capizzi RL
Cancer Treat Rep; 1987 Feb; 71(2):195-6. PubMed ID: 2948640
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC).
Hirabayashi K; Yano J; Takesue H; Fujiwara N; Irimura T
Oncol Res; 1999; 11(11-12):497-504. PubMed ID: 10905561
[TBL] [Abstract][Full Text] [Related]
17. Anticancer activities of orally administered menogaril against human stomach and breast cancers implanted in nude mice.
Inaba M; Sato S; Yamori T; Tashiro T; Ohnishi Y; Maruo K; Ueyama Y; Tsuruo T
Anticancer Res; 1992; 12(6B):1953-6. PubMed ID: 1295442
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of idarubicin, a derivative of daunorubicin, against drug sensitive and resistant P388 leukemia.
Tsuruo T; Oh-Hara T; Sudo Y; Naito M
Anticancer Res; 1993; 13(2):357-61. PubMed ID: 8517647
[TBL] [Abstract][Full Text] [Related]
19. [Antitumor effect of a new anthracycline derivative, MX2, against human glioma cells].
Kuratsu J; Mihara Y; Kochi M; Takaki S; Ushio Y
Gan To Kagaku Ryoho; 1989 Mar; 16(3 Pt 1):399-403. PubMed ID: 2930204
[TBL] [Abstract][Full Text] [Related]
20. Experimental combination chemotherapy of pirarubicin with various antitumor drugs against P388 murine leukemia.
Izumi H; Hirano S; Matsushita Y; Iguchi H; Tone H; Takeuchi T
Cancer Biochem Biophys; 1994 Sep; 14(2):137-49. PubMed ID: 7889494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
